Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.

Détails

ID Serval
serval:BIB_FF42AA3BEB37
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction.
Périodique
Clinical Transplantation
Auteur(s)
Wong W., Tolkoff-Rubin N., Delmonico F.L., Cardarelli F., Saidman S.L., Farrell M.L., Shih V., Winkelmayer W.C., Cosimi A.B., Pascual M.
ISSN
0902-0063[print], 0902-0063[linking]
Statut éditorial
Publié
Date de publication
2004
Volume
18
Numéro
4
Pages
341-348
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Résumé
BACKGROUND: Long-term use of cyclosporine (CsA) contributes to post-transplant cardiovascular disease (CVD). Hence, a reduction in CsA dosage in kidney transplant recipients (KTR) may improve long-term outcomes. We analyzed the effects of 50% CsA dose reduction on the CVD risk profile in stable KTR. METHOD: Thirty-one KTR on a regimen of CsA, prednisone and mycophenolate mofetil (MMF) were studied. Patients were randomized to either a) continue their previously determined CsA dose (control group, n = 15) or b) lower their CsA dose by 50% (CsA reduction group, n = 16). Renal function, blood pressure, lipid profile, plasma homocysteine (HCY), C-reactive protein (CRP), fibrinogen, and uric acid were compared at baseline and at 6 months. RESULTS: At 6 months, there was a significant improvement in allograft function, systolic blood pressure, number of anti-hypertensive medications and serum uric acid levels in the CsA reduction group. No significant decrease in plasma HCY, CRP, fibrinogen or improvement in lipid profile was found. In contrast, in the Control group, there was a significant increase in HCY, uric acid, and triglycerides. No acute rejection occurred in either group. CONCLUSIONS: A greater reduction in CsA dose could further improve CVD risk profiles, although this may increase the risk of acute or subclinical rejection.
Mots-clé
Adult, Blood Pressure, C-Reactive Protein/analysis, Cardiovascular Diseases/epidemiology, Cyclosporine/administration & dosage, Cyclosporine/therapeutic use, Female, Graft Survival, Homocysteine/blood, Humans, Immunosuppressive Agents/administration & dosage, Immunosuppressive Agents/therapeutic use, Kidney Function Tests, Kidney Transplantation, Male, Mycophenolic Acid/analogs & derivatives, Mycophenolic Acid/therapeutic use, Postoperative Period, Prednisolone/therapeutic use, Prospective Studies, Risk Assessment, Risk Factors, Uric Acid/blood
Pubmed
Web of science
Création de la notice
29/01/2008 13:53
Dernière modification de la notice
20/08/2019 16:29
Données d'usage